4 ASX Stocks in Momentum to Buy Now

Momentum is built on conviction as these stocks have the investors backing their rise with other players paying attention to where this trend is heading.

Life360, Inc. (ASX: 360)

has been one of the most notable ASX momentum names this year as it maintained growth and improving profitability from its core subscription business.

In the June 2025 quarter, Life360 delivered total revenue of US$115.4 million which rose from US$84.9 million a year earlier.
The company has turned profitable as it reported net income of US$7 million for the quarter and US$11.4 million for the first half of FY25.

Cash and cash equivalents jumped to US$432.7 million from US$159 million in December 2024, supported by the successful issue of US$320 million in convertible notes, providing flexibility for expansion.

Zip Co Limited (ASX: ZIP)

for the September 2025 quarter posted record cash EBTDA of $62.8 million, up 98% from last year, with total transaction volume reaching $3.9 billion, driven by growth in both Australia and the United States.

The US business continues to be the biggest growth engine, with revenue up 51% year-on-year helped by stronger engagement and strategic partnerships such as Google Pay, Stripe, and Chrome autofill integrations.

Zip also increased its on-market buy-back to $100 million, supported by an impressive cash balance and funding.
The company expects US TTV growth above 40% for FY26 and is exploring a dual listing on the Nasdaq which could further expand its investor base.

Pro Medicus Limited (ASX: PME)

continues to strengthen its position in enterprise imaging and radiology software following another record-breaking year and a string of contracts.

In FY25, the company delivered outstanding financial results with revenue up 31.9% to $213 million, profit after tax rising 39.2% to $115.2 million and ended the year with $210.7 million in cash and investments.

The company’s total forward revenue now exceeds $948 million over five years supported by a strong pipeline across the US and Europe.

PME has expanded into Europe recently by signing a five-year, $10 million deal with University Hospital Heidelberg and the German Cancer Research Institute (DKFZ) to replace three legacy PACS systems. 

IperionX Limited (ASX: IPX)

is doing well as it scales up its titanium manufacturing operations and secures major U.S. government funding to accelerate expansion.

Process improvements and optimization have lifted nameplate titanium powder production capacity by 60% without additional capital.

Titanium manufacturing sales are expected to progressively scale through 2026 with a positive EBITDA by the end of 2026.
A major catalyst for IperionX came from the U.S. Department of War, which has given US$42.5 million to fund the scale-up of operations to 1,400 tonnes per annum by mid-2027.

With a cash balance of US$79.2 million and zero debt, IperionX is well-funded to deliver on its growth roadmap.

(Source: Company Reports)